JPMorgan Downgrades Rapt Therapeutics (RAPT) to Neutral 'on Zelnecirnon Clinical Hold Unknowns'
Tweet Send to a Friend
(Updated - February 21, 2024 4:02 AM EST)
JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (NASDAQ: RAPT) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (NASDAQ: RAPT) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
